CN103284969B - 一种利培酮分散片及其制备方法 - Google Patents
一种利培酮分散片及其制备方法 Download PDFInfo
- Publication number
- CN103284969B CN103284969B CN201310273245.7A CN201310273245A CN103284969B CN 103284969 B CN103284969 B CN 103284969B CN 201310273245 A CN201310273245 A CN 201310273245A CN 103284969 B CN103284969 B CN 103284969B
- Authority
- CN
- China
- Prior art keywords
- risperidone
- dispersible tablet
- preparation
- kollidon
- medicine carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001534 risperidone Drugs 0.000 title claims abstract description 46
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 239000007919 dispersible tablet Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims description 29
- 239000008187 granular material Substances 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 229960004756 ethanol Drugs 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 12
- 238000001035 drying Methods 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000004062 sedimentation Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 3
- 229920003085 Kollidon® CL Polymers 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- YTLYLLTVENPWFT-UPHRSURJSA-N (Z)-3-aminoacrylic acid Chemical class N\C=C/C(O)=O YTLYLLTVENPWFT-UPHRSURJSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 102220042174 rs141655687 Human genes 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Abstract
Description
样品来源 | 溶出度(%) | 崩解时间(s) | 沉降体积比 |
实施例1 | 98.6 | 94 | 0.96 |
实施例2 | 99.4 | 54 | 0.99 |
实施例3 | 99.2 | 59 | 0.97 |
对比实施例1 | 82.1 | 61 | 0.96 |
对比实施例2 | 97.8 | 52 | 0.82 |
对比实施例3 | 65.1 | 364 | 0.97 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310273245.7A CN103284969B (zh) | 2013-07-01 | 2013-07-01 | 一种利培酮分散片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310273245.7A CN103284969B (zh) | 2013-07-01 | 2013-07-01 | 一种利培酮分散片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103284969A CN103284969A (zh) | 2013-09-11 |
CN103284969B true CN103284969B (zh) | 2015-05-27 |
Family
ID=49086866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310273245.7A Active CN103284969B (zh) | 2013-07-01 | 2013-07-01 | 一种利培酮分散片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103284969B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269014A (zh) * | 2007-03-21 | 2008-09-24 | 北京德众万全药物技术开发有限公司 | 一种利培酮的口腔崩解片及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IS7724A (is) * | 2005-03-02 | 2006-09-03 | Actavis Group | Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat |
FR2920311B1 (fr) * | 2007-08-31 | 2010-06-18 | Galenix Innovations | Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation |
-
2013
- 2013-07-01 CN CN201310273245.7A patent/CN103284969B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269014A (zh) * | 2007-03-21 | 2008-09-24 | 北京德众万全药物技术开发有限公司 | 一种利培酮的口腔崩解片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
Formulation and evaluation of orodispersible tablets of stavudine;sellappan velmurugan et al;《International journal of chemical and pharmaceutical sciences》;20120630;第3卷(第2期);第83-92页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103284969A (zh) | 2013-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103491949B (zh) | 片剂型的口服给药用组合物及其制造方法 | |
CN107823170B (zh) | 一种缬沙坦氨氯地平片及其制备方法 | |
CN105878197A (zh) | 利奥西呱口崩片及其制备方法 | |
CN104887633B (zh) | 一种利伐沙班片剂及其制备方法 | |
CN104586854A (zh) | 头孢呋辛酯药物组合物及其制备方法 | |
CN102114001A (zh) | 一种含有托伐普坦的口服固体制剂 | |
CN103284969B (zh) | 一种利培酮分散片及其制备方法 | |
CN106880611A (zh) | 一种含微粉化的托伐普坦和水溶性辅料的托伐普坦制剂 | |
CN101732260A (zh) | 一种盐酸头孢他美酯的颗粒剂及其制备方法 | |
CA2492156C (en) | Tablet composition containing kampo medicinal extract and its manufacturing process | |
CN109700773B (zh) | 一种替格瑞洛制剂组合物及其制备方法 | |
CN106913544B (zh) | 一种快速溶出的吉非替尼片剂及其制备方法 | |
CN102525976B (zh) | 使用流化床制备雷奈酸锶口腔崩解片的方法 | |
CN113577035A (zh) | 一种阿哌沙班片及其制备方法 | |
CN103007286A (zh) | 一种托伐普坦的固体药物组合物 | |
CN103006614B (zh) | 一种遇水呈非凝胶状态的头孢呋辛酯胶囊及其制备方法 | |
Sarkar et al. | Microcrystalline cellulose: An overview | |
CN106668027A (zh) | 奥贝胆酸药物组合物及其制备方法 | |
CN104490790A (zh) | 头孢呋辛酯固体分散体包衣组合物及其制备方法 | |
CN105287414A (zh) | 一种含有利伐沙班的固体药物组合物及其制备方法 | |
CN110960501A (zh) | 一种诺氟沙星胶囊及其制备方法 | |
CN105555316A (zh) | 通过二阶段的湿式制粒工序制备的崩解性颗粒组合物及含有该组合物的口腔内崩解片剂 | |
JPWO2017209216A1 (ja) | 難溶性薬物の微粒子を含有する医薬組成物の製造方法 | |
CN104248625B (zh) | 阿伐那非泡腾干混悬剂及其制备方法 | |
JPH0153253B2 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 225324 Jiangsu province Taizhou Gaogang Xu Zhuang Street Minghe Village No. 53 Patentee after: NANJING ZHENGKUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 211200 Lishui Economic Development Zone, Jiangsu, Nanjing No. 1 Shandong Road Patentee before: NANJING ZHENGKUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 211200 Lishui Economic Development Zone, Jiangsu, Nanjing No. 1 Shandong Road Patentee after: NANJING ZHENGKUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 225324 Jiangsu province Taizhou Gaogang Xu Zhuang Street Minghe Village No. 53 Patentee before: NANJING ZHENGKUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180810 Address after: 315000 396 Pearl Road, hi tech Zone, Ningbo, Zhejiang Patentee after: NINGBO DAHONGYING MEDICINE Co.,Ltd. Address before: 211200 No. 1 Shandong Road, Lishui Economic Development Zone, Nanjing, Jiangsu. Patentee before: NANJING ZHENGKUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 317 Xiaogang Anju Road, Beilun District, Ningbo City, Zhejiang Province Patentee after: NINGBO DAHONGYING MEDICINE Co.,Ltd. Address before: 315000 396 Pearl Road, hi tech Zone, Ningbo, Zhejiang Patentee before: NINGBO DAHONGYING MEDICINE Co.,Ltd. |